S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure

Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2014) S. Cereda et al.   JOURNAL OF CHEMOTHERAPY

Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer

(2010) Anna Novarino et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy

(2008) M Reni et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

(2008) Yoon Jae Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

(2008) Seong Yoon Yi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

(2008) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

(2008) Andrew H. Ko et al.   CANCER INVESTIGATION